Pulmonary hypertension in the setting of interstitial lung disease: Approach to management and treatment. A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative-Group 3 Pulmonary Hypertension.

Pulm Circ · 2024 · PMC10777777 · PMID 38205098

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

96 In the single arm studies, there was a significant improvement in 6MWD (46.2 m; 95% CI, 27.9–64.4), whereas in the RCTs the improvement did not reach statistical significance (21.6 m; 95% CI, −17.8 to 61.0).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.